Ananda Developments PLC THC Oil Patent Application Filed (6882S)
2023年11月8日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMANA
RNS Number : 6882S
Ananda Developments PLC
08 November 2023
8 November 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
THC Oil Patent Application Filed
Ananda Developments plc (AQSE: ANA), a company whose ambition is
to be a leading provider of cannabinoid-based medicines for the
treatment of chronic, complex inflammatory pain conditions, is
pleased to announce that its wholly owned subsidiary MRX Medical
Limited (MRX) has filed a fifth patent application with the UK
Government's Intellectual Property Office.
The application covers a new cannabinoid formulation known as
MRX2T. This formulation is based on MRX's patent pending MRX2
cannabidiol formulation, with the addition of tetrahydrocannabinol
(THC). This formulation has been developed for use in Randomised
Controlled Trials (RCTs) and the Company looks forward to updating
shareholders in due course.
This application is in addition to four previous applications
which cover the proprietary formulation methodology and three
different cannabinoid formulations known as MRX1, MRX2 and MRX3.
MRX1 will be used as the investigational medicinal product (IMP) in
two Phase II RCTs being conducted by the University of Edinburgh.
One trial is investigating the effect of CBD on pain associated
with chemotherapy induced peripheral neuropathy (CIPN) and the
other is investigating the effect of cannabidiol on pain associated
with endometriosis.
Ananda's CEO, Melissa Sturgess, commented: "We are building
Ananda's intellectual property with the application for a fifth
patent covering an oil formulation containing THC as well as CBD.
We are hopeful this oil will be used in randomised controlled
trials and look forward to bringing shareholders an update on this
as soon as possible."
To stay abreast of the latest developments at Ananda, we
encourage you to follow our social media channels which are:
-- Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
-- LinkedIn : https://www.linkedin.com/company/anadevelopments/
-- Twitter : https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
ir@anandadevelopments.com
Chief Executive Officer
Melissa Sturgess
Executive Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE
LLP +44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a
leading provider of cannabinoid-based medicines for the treatment
of complex, chronic inflammatory pain conditions.
For more information, please visit:
https://anandadevelopments.com/
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXUBUNROAUARAA
(END) Dow Jones Newswires
November 08, 2023 02:00 ET (07:00 GMT)
Ananda Developments (AQSE:ANA)
過去 株価チャート
から 11 2024 まで 12 2024
Ananda Developments (AQSE:ANA)
過去 株価チャート
から 12 2023 まで 12 2024